Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

DSpace Repository

Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Author: Powell, Matthew A.; Cibula, David; O'Malley, David M.; Boere, Ingrid; Shahin, Mark S.; Savarese, Antonella; Chase, Dana M.; Gilbert, Lucy; Black, Destin; Herrstedt, Jorn; Sharma, Sudarshan; Kommoss, Stefan; Gold, Michael A.; Thijs, Anna M.; Ring, Kari; Bolling, Magnus Frodin; Buscema, Joseph; Gill, Sarah E.; Nowicki, Paul; Nevadunsky, Nicole; Callahan, Michael; Willmott, Lyndsay; McCourt, Carolyn; Billingsley, Caroline; Ghamande, Sharad A.; He, Zangdong; Balas, Morad Marco; Stevens, Shadi; Fleming, Evelyn; Mirza, Mansoor Raza
Tübinger Autor(en):
Kommoss, Stefan
Published in: Gynecologic Oncology (2025), Bd. 192, S. 40-49
Verlagsangabe: San Diego : Academic Press Inc Elsevier Science
Language: English
Full text: http://dx.doi.org/10.1016/j.ygyno.2024.10.022
ISSN: 0090-8258
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)